Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 189.55

+3.5%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mudcat who wrote (24717)	8/19/1998 12:21:00 AM
From: Henry Niman	Read Replies (2) of 32384

Mudcat, I thought that your question was rhetorical, because I had already answered it this morning. However, it sounds like you really don't understand, so I'll try again. First I do find it odd that someone would try to represent a $0.05 revision as a 167% decrease. If you want to use percentages then why not use the revised numbers and say that the $0.02 loss in 4Q is an over 1000% improvement over the $0.21 loss projected for the previous quarter. 1000% improvement in just 3 months!!! Your percentages are simply absurd, but I'll answer the rest of your question. The BUY rec (highest rating and no speculative rating as our naysayer misrepresents) takes many things into account. Both revised quarters show an improvement over earlier quarters this year ($0.21 and $0.02 revised losses compared to $0.40 and $0.45 for the first 2 quarters this year or $0.35 and $0.09 for the last two quarters last year. What's more remarkable is the improvements without the ALRT income or the up front payment from LLY in 4Q last year. However, these numbers are not as important as the projected profit for 1999 which remains at $0.09. At the top of the rec are several important items. One is LGND's closing price yesterday, 8 9/16. Th other items are the three bullets: *Finanicials in line with expectations, although immaterial to fundamental outlook ONTAK, Panretin Topical moving toward approval Continued sell-off unwarranted, recommend investors take advantage prior to spate of second half events Thus Bear Stearns is looking at the overall picture. The see that the product approvals are moving forward and the projected profits for next year remain unchanged. They also look at LGND's closing price as of yesterday. They see no reason for the decline and would recommend investors seriously examine the upside potential in the stock at current levels**. They also list 5 highlights for 2H '98. It's not that hard to see that LGND is a screaming buy at these levels. It appears that many agree. Volume was about 3/4 million and the price moved to 9 1/4 with heavy buying at the close: quote.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next